Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury.
To investigate the inhibitory effect of serine protease inhibitors (SPI) on neutrophil-mediated endothelial cell (EC) injury, we analyzed the in vitro cytotoxicity of radiolabeled human umbilical vein EC (HUVEC) mediated by neutrophils in the presence of SPI. The EC injury was inhibited dose-dependently by urinary trypsin inhibitor (ulinastatin, UTI) and ONO-5046, which have the ability to inactivate neutrophil elastase, but not by gabexate mesilate, nafamostat mesilate, aprotinin, and argatroban, which have no ability to inactivate neutrophil elastase. In addition, when UTI and ONO-5046 were added to the tumor necrosis factor alpha-primed neutrophils alone, they showed a dose-dependent inhibition of the intracellular elastase activity, but the other SPI did not, for either flow cytometry or confocal microscopy. Therefore, UTI and ONO-5046 may protect EC against the neutrophil-mediated injury not only by inactivating the extracellular elastase secreted by neutrophils, but also by acting directly on neutrophils and suppressing the production and secretion of activated elastase from them.
Nakatani
K
K
Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama, Japan.
Takeshita
S
S
Tsujimoto
H
H
Kawamura
Y
Y
Sekine
I
I
D002478:Cells, Cultured; D004338:Drug Combinations; D004730:Endothelium, Vascular / Q000187:drug effects / Q000201:enzymology / Q000276:immunology* / Q000473:pathology*; D005434:Flow Cytometry; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006023:Glycoproteins / Q000494:pharmacology; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D007424:Intracellular Fluid / Q000187:drug effects / Q000201:enzymology; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D008070:Lipopolysaccharides / Q000494:pharmacology; D018613:Microscopy, Confocal; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D018375:Neutrophil Activation / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology* / Q000276:immunology*; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014361:Trypsin Inhibitors / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014471:Umbilical Veins
D004338:Drug Combinations; D006023:Glycoproteins; D007375:Interleukin-1; D008070:Lipopolysaccharides; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; D014361:Trypsin Inhibitors; D014409:Tumor Necrosis Factor-alpha; D009240:N-Formylmethionine Leucyl-Phenylalanine; D007371:Interferon-gamma; C069195:sivelestat; D019272:Leukocyte Elastase; D013755:Tetradecanoylphorbol Acetate; C028665:urinastatin; D005998:Glycine; C012655:nimesulide